• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Tesaro makes its case for a clean sweep with ni­ra­parib - and shares soar again

9 years ago
R&D

Kite touts 12-month re­mis­sion da­ta from tiny CAR-T study; Iron­wood ex­ec dies in bike ac­ci­dent

9 years ago
News Briefing

Thumbs Up/Thumbs Down: Ma­jor in­sur­er de­liv­ers a bad blow to Duchenne fam­i­lies

9 years ago
Bioregnum
Opinion

Clo­vis shares tank af­ter in­vestors size up the dis­ap­point­ing da­ta on ru­ca­parib

9 years ago
R&D

Up­dat­ed In­cyte com­bo da­ta for epaca­do­stat/Keytru­da look promis­ing

9 years ago
R&D

Lethal ex­per­i­men­tal can­cer drug from Han­mi, Boehringer killed three pa­tients — re­port

9 years ago
R&D

Pfiz­er plots a big move (but it's not go­ing very far)

9 years ago
Pharma

Medicxi launch­es a di­a­betes up­start with $11M; Ar­row­head part­ners on hep B; Im­munother­a­py start­up gains $12.2M round

9 years ago
News Briefing

Reuters probe spot­lights a con­flict of in­ter­est be­tween biotech in­vestor F-Prime and gi­ant Fi­deli­ty

9 years ago
Financing

Te­va hands Cell­tri­on $160M to grab US rights on two biosim­i­lars of Roche block­busters

9 years ago
R&D
Pharma

Pi­lot project pro­vides a snap­shot of ef­fec­tive­ness of Pfiz­er’s PARP con­tender ta­la­zoparib

9 years ago
R&D

Feds help NewLink, Mer­ck out with some added cash for Ebo­la vac­cine

9 years ago
R&D
Pharma

Al­ny­lam shares crater af­ter tri­al deaths force in­ves­ti­ga­tors to scrap PhI­II RNAi drug

9 years ago
R&D

Can We Con­quer All Dis­eases By The End Of The Cen­tu­ry? An In­ter­view with Chan Zucker­berg's Cori Bargmann.

9 years ago
People

UK start­up tack­les hot neoanti­gen field in can­cer drugs

9 years ago
Financing
Startups

Biotech bil­lion­aire backs a food al­ler­gy/nu­tri­tion start­up; Ed­i­tas re­cruits a CMO

9 years ago
News Briefing

An­dré Chouli­ka on gene edit­ing: "If you mar­ry your­self to a tech­nol­o­gy, you're doomed."

9 years ago
People

As­traZeneca jet­ti­sons an­oth­er drug, this time grab­bing $30M for out-li­cens­ing deal

9 years ago
R&D

Hold the ap­plause: Big Phar­ma has lit­tle to brag about re­gard­ing 2016 R&D pro­duc­tiv­i­ty

9 years ago
R&D
Pharma

No­var­tis un­veils a new glob­al R&D struc­ture, cre­at­ing cen­ters in Cam­bridge, MA and Basel

9 years ago
R&D
Pharma

No­var­tis is up­root­ing an­oth­er re­search group in on­go­ing glob­al re­or­ga­ni­za­tion

9 years ago
R&D
Pharma

Sam­sung BioEpis pitch­es Her­ceptin biosim­i­lar as par­ent com­pa­ny hunts $2B IPO; Chi­as­ma CEO is out

9 years ago
News Briefing

Hus­tling to cap­ture top front­line NSCLC sta­tus, Roche scores a ‘break­through’ on Ale­cen­sa

9 years ago
R&D

Am­gen joins a mar­quee list of part­ners jump­ing on Nuevo­lu­tion’s dis­cov­ery plat­form

9 years ago
R&D
Pharma
First page Previous page 1160116111621163116411651166 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News